Demyelinating disorders. Cousins of MS updated.

A forum to discuss research on the origins of MS and its development.

Demyelinating disorders. Cousins of MS updated.

Postby frodo » Tue Jun 19, 2018 5:03 am

An interesting diagram speaking about Anti-MOG associated encephalomyelitis. Some MS cases could be anti-MOG in reality. Get informed.


      Image

      Clinical spectrum of myelin oligodendrocyte glycoprotein (MOG) immunoglobulin-G (IgG)-associated disease. MOG-IgG is detected in some cases of idiopathic optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), encephalitides (brainstem and cerebral cortical), idiopathic myelitis, atypical multiple sclerosis (MS), aquaporin-4 (AQP4)-IgG-negative neuromyelitis optica spectrum disorders (NMOSD) and others.


Source: http://onlinelibrary.wiley.com/doi/10.1 ... 12434/full
User avatar
frodo
Family Elder
 
Posts: 1149
Joined: Wed Dec 02, 2009 3:00 pm

Advertisement

Update: Intermediate cases between MS and NMO

Postby frodo » Tue Jun 19, 2018 5:05 am

Update: Intermediate cases between MS and NMO

B cell depleting therapy for multiple sclerosis overlapping with neuromyelitis optica spectrum disorder

https://www.sciencedirect.com/science/a ... 4818301123

Highlights

• Description of a typical case of MS overlapping with NMOSD.
• Humoral immunity as appropriate target for MS and NMOSD overlapping disorders.
• B cell depleting agents may be preferred for challenging demyelinating cases.

Abstract

Multiple sclerosis and neuromyelitis optica spectrum disorder are currently thought to be independent entities. Some patients display intermediate manifestations that fit the criteria for both diseases without positive relevant serobiomarkers. An overall standard and consensus for the diagnosis and treatment of these overlapping patients have not been reached. We describe a patient with frequently relapsing demyelinating episodes and repeatedly adjusted treatment regimens due to diagnostic difficulties. This case did not respond adequately to glucocorticoid plus azathioprine or to interferon. Benefits were finally obtained by using rituximab, an anti-CD20 specific monoclonal antibody targeting B cells. Treatments targeting B cell mediated humoral immunity such as rituximab, may be a safe and appropriate choice for these challenging demyelinating cases, especially in Asian population.
User avatar
frodo
Family Elder
 
Posts: 1149
Joined: Wed Dec 02, 2009 3:00 pm


Return to MS Etiology and Pathogenesis

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service